Vivos Therapeutics (VVOS) Other financing activities (2021 - 2026)

Vivos Therapeutics (VVOS) has 4 years of Other financing activities data on file, last reported at $487000.0 in Q1 2026.

• Other financing activities for Q1 2026 came in at $487000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $987000.0 (changed N/A YoY), and the FY2025 annual result was $837000.0, down 38.5% from the prior year.
• Other financing activities slipped to $487000.0 in Q1 2026 per VVOS's latest filing, from $500000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $645000.0 in Q1 2023 and troughed at $100000.0 in Q2 2024.
• A 3-year average of $425571.4 and a median of $487000.0 in 2026 frame the typical range for Other financing activities.
• On a YoY basis, Other financing activities climbed as much as 15.74% in 2024 and fell as far as 52.56% in 2024.
• A 3-year view of Other financing activities shows it stood at $432000.0 in 2023, then increased by 15.74% to $500000.0 in 2024, then declined by 2.6% to $487000.0 in 2026.
• Business Quant data shows VVOS's Other financing activities at $487000.0 in Q1 2026, $500000.0 in Q4 2024, and $509000.0 in Q3 2024.